CO2017010631A2 - Método para purificación de proteína - Google Patents
Método para purificación de proteínaInfo
- Publication number
- CO2017010631A2 CO2017010631A2 CONC2017/0010631A CO2017010631A CO2017010631A2 CO 2017010631 A2 CO2017010631 A2 CO 2017010631A2 CO 2017010631 A CO2017010631 A CO 2017010631A CO 2017010631 A2 CO2017010631 A2 CO 2017010631A2
- Authority
- CO
- Colombia
- Prior art keywords
- monomeric
- domain
- human
- antibody
- protein purification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona un método para recuperar un anticuerpo que contiene un dominio VH3 humano en forma monomérica. En particular, la presente invención proporciona un nuevo método que permite la recuperación de anticuerpos monoméricos que contienen el dominio VH3 humano a partir de una mezcla que contiene formas monoméricas y multiméricas del anticuerpo. El particular, el método reclamado comprende: a) aplicar una mezcla que comprende un anticuerpo que contiene el dominio VH3 humano en forma monomérica y multimérica a un material de cromatografía de proteína A y b) la recuperación del anticuerpo que contiene el dominio VH3 humano, en forma monomérica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506868.7A GB201506868D0 (en) | 2015-04-22 | 2015-04-22 | Method for protein purification |
| PCT/EP2016/058774 WO2016169992A1 (en) | 2015-04-22 | 2016-04-20 | Method for protein purification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017010631A2 true CO2017010631A2 (es) | 2018-01-05 |
Family
ID=53299017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0010631A CO2017010631A2 (es) | 2015-04-22 | 2017-10-18 | Método para purificación de proteína |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10927164B2 (es) |
| EP (1) | EP3286205A1 (es) |
| JP (2) | JP6866300B2 (es) |
| KR (1) | KR102675400B1 (es) |
| CN (1) | CN107636012B (es) |
| AR (1) | AR104358A1 (es) |
| AU (1) | AU2016251223B2 (es) |
| BR (1) | BR112017022073A2 (es) |
| CA (1) | CA2983057A1 (es) |
| CL (1) | CL2017002614A1 (es) |
| CO (1) | CO2017010631A2 (es) |
| EA (1) | EA201792328A1 (es) |
| GB (1) | GB201506868D0 (es) |
| IL (1) | IL254883B (es) |
| MA (1) | MA41941A (es) |
| MX (1) | MX2017013333A (es) |
| MY (1) | MY189854A (es) |
| SG (1) | SG11201708256YA (es) |
| WO (1) | WO2016169992A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013081540A1 (en) * | 2011-11-30 | 2013-06-06 | Ge Healthcare Bio-Sciences Ab | Affinity chromatography matrix |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| CN108085358A (zh) * | 2018-02-08 | 2018-05-29 | 保定冀中药业有限公司 | 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法 |
| CN114401984A (zh) | 2019-08-02 | 2022-04-26 | Ucb生物制药有限责任公司 | 纯化抗体的方法 |
| GB201919058D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| WO2021130717A1 (ko) * | 2019-12-26 | 2021-07-01 | 에이비엘바이오 주식회사 | 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법 |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| JP2002544237A (ja) | 1999-05-15 | 2002-12-24 | ユニバーシティ オブ カリフォルニア，サン ディエゴ | 望ましい活性を有するプロテインａに基づく結合ドメイン |
| WO2002059264A2 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General Corp. | Specific human antibodies for selective cancer therapy |
| WO2004087761A1 (ja) * | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| WO2010019493A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| UY32451A (es) * | 2009-02-17 | 2010-09-30 | Ucb Pharma Sa | Moléculas de anticuerpo con especifidad por el ox40 humano |
| MX2013004720A (es) * | 2010-11-01 | 2013-05-28 | Dsm Ip Assets Bv | Purificacion de anticuerpos mediante cromatografia de intercambio ionico de una uncia unidad. |
| WO2012074463A1 (en) | 2010-11-29 | 2012-06-07 | Ge Healthcare Bio-Sciences Ab | Affinity chromatography matrix |
| US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| JP6486686B2 (ja) * | 2012-02-10 | 2019-03-20 | ジェネンテック， インコーポレイテッド | 単鎖抗体及び他のヘテロ多量体 |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| AU2014343636A1 (en) * | 2013-11-04 | 2016-06-02 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2015
- 2015-04-22 GB GBGB1506868.7A patent/GB201506868D0/en not_active Ceased
-
2016
- 2016-04-20 BR BR112017022073A patent/BR112017022073A2/pt active Search and Examination
- 2016-04-20 AU AU2016251223A patent/AU2016251223B2/en active Active
- 2016-04-20 US US15/566,231 patent/US10927164B2/en active Active
- 2016-04-20 SG SG11201708256YA patent/SG11201708256YA/en unknown
- 2016-04-20 CA CA2983057A patent/CA2983057A1/en active Pending
- 2016-04-20 EA EA201792328A patent/EA201792328A1/ru unknown
- 2016-04-20 CN CN201680028589.3A patent/CN107636012B/zh active Active
- 2016-04-20 MA MA041941A patent/MA41941A/fr unknown
- 2016-04-20 MX MX2017013333A patent/MX2017013333A/es unknown
- 2016-04-20 JP JP2017555232A patent/JP6866300B2/ja active Active
- 2016-04-20 EP EP16717915.9A patent/EP3286205A1/en active Pending
- 2016-04-20 KR KR1020177033687A patent/KR102675400B1/ko active IP Right Grant
- 2016-04-20 MY MYPI2017703933A patent/MY189854A/en unknown
- 2016-04-20 WO PCT/EP2016/058774 patent/WO2016169992A1/en active Application Filing
- 2016-04-22 AR ARP160101122A patent/AR104358A1/es unknown
-
2017
- 2017-10-03 IL IL254883A patent/IL254883B/en unknown
- 2017-10-16 CL CL2017002614A patent/CL2017002614A1/es unknown
- 2017-10-18 CO CONC2017/0010631A patent/CO2017010631A2/es unknown
-
2021
- 2021-01-07 JP JP2021001584A patent/JP2021066734A/ja not_active Abandoned
- 2021-02-17 US US17/177,236 patent/US20210171609A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201506868D0 (en) | 2015-06-03 |
| KR20170139131A (ko) | 2017-12-18 |
| EA201792328A1 (ru) | 2018-05-31 |
| CA2983057A1 (en) | 2016-10-27 |
| BR112017022073A2 (pt) | 2018-08-14 |
| AR104358A1 (es) | 2017-07-12 |
| MX2017013333A (es) | 2018-02-19 |
| CN107636012A (zh) | 2018-01-26 |
| US10927164B2 (en) | 2021-02-23 |
| AU2016251223B2 (en) | 2021-12-09 |
| MY189854A (en) | 2022-03-14 |
| MA41941A (fr) | 2018-02-28 |
| CL2017002614A1 (es) | 2018-04-27 |
| IL254883A0 (en) | 2017-12-31 |
| JP6866300B2 (ja) | 2021-04-28 |
| AU2016251223A1 (en) | 2017-10-26 |
| SG11201708256YA (en) | 2017-11-29 |
| IL254883B (en) | 2021-09-30 |
| US20180100007A1 (en) | 2018-04-12 |
| WO2016169992A1 (en) | 2016-10-27 |
| CN107636012B (zh) | 2022-08-02 |
| US20210171609A1 (en) | 2021-06-10 |
| KR102675400B1 (ko) | 2024-06-13 |
| JP2018520089A (ja) | 2018-07-26 |
| JP2021066734A (ja) | 2021-04-30 |
| EP3286205A1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017010631A2 (es) | Método para purificación de proteína | |
| EA202092435A3 (ru) | Моноклональные антитела против bcma | |
| CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
| CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| EA201990293A1 (ru) | Мультиспецифичные антитела против cd40 и cd137 | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
| EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| EA201790719A1 (ru) | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения | |
| NZ727020A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
| EP3561057A4 (en) | ANTI-CD3 ANTIBODY AND MOLECULE CONTAINING LEDIT ANTIBODY | |
| UY36678A (es) | Anticuerpos anti-fcrn. | |
| CO2020002060A2 (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn |